Increlex for growth failure in children

Ipsen has launched Increlex (mecasermin) for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 (IGF-1) deficiency.

PHARMACOLOGY
Mecasermin is a human IGF-1 produced by recombinant DNA technology.

IGF–1 is the principal hormonal mediator of growth. In target tissues, IGF–1 activates the IGF–1 receptor, leading to intracellular signalling to induce and support statural growth. IGF–1 induces the uptake of glucose, fatty acids and amino acids so that metabolism supports growing tissues.

Further information: Ipsen 01753 627777

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Medicines shortages increase as prescribing costs rise £158 million

Medicines shortages increase as prescribing costs rise £158 million

Increasing medicines shortages have added more than...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MHRA urges GPs to ensure continued INR monitoring during pandemic

MHRA urges GPs to ensure continued INR monitoring during pandemic

The MHRA advice was issued following reports of an...